Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
- PMID: 19898421
- DOI: 10.1038/modpathol.2009.159
Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
Abstract
Androgens exert growth inhibitory effects on estrogen receptor and progesterone receptor-negative breast cancer cell lines that show androgen receptor expression. These laboratory findings may be translated into inexpensive alternative therapies for hormone receptor-negative invasive breast cancers. Our aim was to systematically evaluate androgen receptor expression by immunohistochemistry in invasive breast cancers. Androgen receptor (clone AR441, Dako) expression was analyzed on 189 well-characterized consecutive invasive breast carcinomas represented with threefold redundancy on tissue microarrays. Androgen receptor expression was semi-quantitated using a histochemical score-like method and a score >10 was considered positive. Of the 189 consecutive invasive breast cancers, 151 (80%) were positive and 38 (20%) were negative for androgen receptor. The majority (95%) of estrogen receptor-positive tumors were also androgen receptor positive. Of the estrogen receptor-negative tumors, androgen receptor reactivity was seen in 3 of 30 (10%) triple-negative cases and in 5/8 (63%) estrogen receptor-negative/progesterone receptor-negative/HER2+ cases. Six of eight estrogen receptor-negative/androgen receptor-positive cases showed apocrine differentiation. Androgen receptor expression in estrogen receptor-positive cases was associated with smaller tumor size (P=0.0001), lower Nottingham grade (P=0.002) and less frequent tumor cell necrosis (P=0.0001). Androgen receptor expression in estrogen receptor-negative tumors was associated with lower Nottingham grade (P=0.005) and apocrine differentiation (P=0.039). In conclusion, most estrogen receptor-positive breast tumors also express androgen receptor. Androgen receptor expression in estrogen receptor-negative/progesterone receptor-negative/HER2+ tumors (which commonly show apocrine differentiation) and a subset of triple - negative apocrine tumors suggest that these tumors together comprises the 'molecular apocrine' group described previously. However, these findings should be further confirmed on larger series of triple-negative and estrogen negative/progesterone negative/HER2+ tumors. Androgen receptor-targeted therapy in estrogen/progesterone receptor-negative tumors may provide an inexpensive alternative to usual high-dose chemotherapy with or without trastuzumab.
Similar articles
-
An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast.Clin Breast Cancer. 2022 Jun;22(4):e576-e585. doi: 10.1016/j.clbc.2021.12.009. Epub 2021 Dec 27. Clin Breast Cancer. 2022. PMID: 35027319 Review.
-
Prevalence of androgen receptors in invasive breast carcinoma and its relation with estrogen receptor, progesterone receptor and Her2/neu expression.J Egypt Natl Canc Inst. 2012 Jun;24(2):77-83. doi: 10.1016/j.jnci.2012.04.001. Epub 2012 May 15. J Egypt Natl Canc Inst. 2012. PMID: 23582599
-
Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.Jpn J Clin Oncol. 2012 May;42(5):375-86. doi: 10.1093/jjco/hys034. Epub 2012 Mar 26. Jpn J Clin Oncol. 2012. PMID: 22450930
-
Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.Mod Pathol. 2011 Jul;24(7):924-31. doi: 10.1038/modpathol.2011.54. Epub 2011 May 6. Mod Pathol. 2011. PMID: 21552212 Free PMC article.
-
Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.Mod Pathol. 2010 May;23 Suppl 2:S52-9. doi: 10.1038/modpathol.2010.55. Mod Pathol. 2010. PMID: 20436503 Review.
Cited by
-
Incidence and Prognostic Significance of Androgen Receptors (AR) in Indian Triple-Negative Breast Cancer (TNBC).Indian J Surg Oncol. 2024 Jun;15(2):250-257. doi: 10.1007/s13193-024-01877-2. Epub 2024 Jan 15. Indian J Surg Oncol. 2024. PMID: 38741650
-
The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management.Cancers (Basel). 2023 Nov 17;15(22):5463. doi: 10.3390/cancers15225463. Cancers (Basel). 2023. PMID: 38001722 Free PMC article. Review.
-
Divergent features of ERβ isoforms in triple negative breast cancer: progress and implications for further research.Front Cell Dev Biol. 2023 Oct 23;11:1240386. doi: 10.3389/fcell.2023.1240386. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37936981 Free PMC article. Review.
-
Circular RNAs: biology and clinical significance of breast cancer.RNA Biol. 2023 Jan;20(1):859-874. doi: 10.1080/15476286.2023.2272468. Epub 2023 Oct 26. RNA Biol. 2023. PMID: 37882644 Free PMC article. Review.
-
Unveiling the Anti-Cancer Potential of Onoceranoid Triterpenes from Lansium domesticum Corr. cv. kokosan: An In Silico Study against Estrogen Receptor Alpha.Int J Mol Sci. 2023 Oct 9;24(19):15033. doi: 10.3390/ijms241915033. Int J Mol Sci. 2023. PMID: 37834479 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous